Dr Deepak Balaji Thimiri Govindaraj, Centre Manager, CSIR Synthetic Biology and Precision Medicine Centre
The gold standard treatment of ovarian cancer comprises platinum-based chemotherapeutic agents that bind DNA and cause cells to undergo apoptosis. However, the frequent emergence of drug resistance causes patients to relapse. Therefore, new treatment strategies are required. To address this unmet medical need, an international collaborative project led by the CSIR will develop a pipeline for the identification of drugs and drug combinations capable of overcoming platinum resistance. The cutting-edge technology will combine tissue engineering, chemical synthesis and microfluidic technology. It will help screen drugs in patients with relapsed ovarian cancer who have exhausted all other treatment options, offering tailored alternatives.